ATE249472T1 - Nukleosid-monophosphatderivate, verfahren zu deren herstellung sowie deren verwendung als immunsuppressive arzneimittel - Google Patents

Nukleosid-monophosphatderivate, verfahren zu deren herstellung sowie deren verwendung als immunsuppressive arzneimittel

Info

Publication number: ATE249472T1
Authority: AT; Austria
Prior art keywords: desoxy; chain; nucleoside monophosphate; production; monophosphate derivatives
Prior art date: 1994-05-28

Application number

AT02008360T

Other languages

English (en)

Inventor

Dieter Herrmann

Harald Zilch

Alfred Mertens

Original Assignee

Heidelberg Pharma Holding Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-28

Filing date

1995-05-23

Publication date

2003-09-15

1995-05-23 Application filed by Heidelberg Pharma Holding Gmbh filed Critical Heidelberg Pharma Holding Gmbh

2003-09-15 Application granted granted Critical

2003-09-15 Publication of ATE249472T1 publication Critical patent/ATE249472T1/de

Links

-1 NUCLEOSIDE MONOPHOSPHATE Chemical class 0.000 title abstract 2
239000003814 drug Substances 0.000 title abstract 2
229940079593 drug Drugs 0.000 title abstract 2
239000002777 nucleoside Substances 0.000 title abstract 2
230000001506 immunosuppresive effect Effects 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
AYWFLOPQIYDGTP-RJDJZVBFSA-N (2R,3S,4R,5R)-4-amino-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol 4-amino-1-[(2R,3R,4S,5R)-3-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one (2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol (2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-azido-2-(hydroxymethyl)oxolan-3-ol 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound FC=1N=C(C=2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2N1)N.FC=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C1)=O)=O.N(=[N+]=[N-])[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C(=O)N=C(N)C=C1.N(=[N+]=[N-])[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(N)=NC=NC12.N[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(N)=NC=NC12 AYWFLOPQIYDGTP-RJDJZVBFSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
150000007522 mineralic acids Chemical class 0.000 abstract 1
150000007524 organic acids Chemical class 0.000 abstract 1
235000005985 organic acids Nutrition 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Virology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AT02008360T 1994-05-28 1995-05-23 Nukleosid-monophosphatderivate, verfahren zu deren herstellung sowie deren verwendung als immunsuppressive arzneimittel ATE249472T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4418690A DE4418690A1 (de)	1994-05-28	1994-05-28	Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel

Publications (1)

Publication Number	Publication Date
ATE249472T1 true ATE249472T1 (de)	2003-09-15

Family

ID=6519215

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT95920864T ATE236189T1 (de)	1994-05-28	1995-05-23	Nukleosid-monophosphatderivate, verfahren zu deren herstellung sowie deren verwendung als immunsuppresive arzneimittel
AT02008360T ATE249472T1 (de)	1994-05-28	1995-05-23	Nukleosid-monophosphatderivate, verfahren zu deren herstellung sowie deren verwendung als immunsuppressive arzneimittel

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT95920864T ATE236189T1 (de)	1994-05-28	1995-05-23	Nukleosid-monophosphatderivate, verfahren zu deren herstellung sowie deren verwendung als immunsuppresive arzneimittel

Country Status (27)

Country	Link
US (1)	US6025343A (de)
EP (2)	EP0763049B1 (de)
JP (1)	JP3802057B2 (de)
KR (1)	KR100279087B1 (de)
CN (1)	CN1168735C (de)
AT (2)	ATE236189T1 (de)
AU (1)	AU688516B2 (de)
BR (1)	BR9507785A (de)
CA (1)	CA2190983C (de)
CZ (1)	CZ291846B6 (de)
DE (3)	DE4418690A1 (de)
DK (2)	DK0763049T3 (de)
ES (2)	ES2199250T3 (de)
FI (1)	FI117673B (de)
HU (1)	HU220336B (de)
IL (1)	IL113865A (de)
MX (1)	MX9605809A (de)
NO (1)	NO308998B1 (de)
NZ (1)	NZ287434A (de)
PL (1)	PL185290B1 (de)
PT (2)	PT763049E (de)
RU (1)	RU2165429C2 (de)
SK (1)	SK284207B6 (de)
TW (1)	TW420686B (de)
UA (1)	UA45339C2 (de)
WO (1)	WO1995032984A1 (de)
ZA (1)	ZA954374B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458772B1 (en)	1909-10-07	2002-10-01	Medivir Ab	Prodrugs
JP3839857B2 (ja) *	1994-09-20	2006-11-01	塩野義製薬株式会社	エーテル型チオリン脂質化合物の製造方法
JP3142874B2 (ja) *	1994-12-13	2001-03-07	彰松田	３´−置換ヌクレオシド誘導体
WO1999051613A1 (en) *	1998-04-03	1999-10-14	Medivir Ab	Prodrugs of phosphorous-containing pharmaceuticals
US6407077B1 (en)	1998-11-05	2002-06-18	Emory University	β-L nucleosides for the treatment of HIV infection
EP1124839B1 (de)	1998-11-05	2006-01-11	Centre National De La Recherche Scientifique (Cnrs)	Nukleoside mit anti-hepatitis b virus wirkung
DE19855963A1 (de) *	1998-12-04	2000-06-08	Herbert Schott	Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
US7026469B2 (en)	2000-10-19	2006-04-11	Wake Forest University School Of Medicine	Compositions and methods of double-targeting virus infections and cancer cells
AU1916201A (en)	1999-11-08	2001-06-06	Origenix Technologies, Inc.	Combinatorial library synthesis and pharmaceutically active compounds produced thereby
US6787526B1 (en)	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en)	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002057498A1 (en) *	2001-01-22	2002-07-25	Emergen, Inc.	Isotopically enriched nucleic acids and associated methods for the production and purification thereof
WO2002092006A2 (en)	2001-05-16	2002-11-21	Micrologix Biotech, Inc.	Nucleic acid-based compounds and methods of use thereof
CA2468099A1 (en) *	2001-11-21	2003-05-30	Ganymed 256 Vermogensverwaltungs Gmbh	Phospholipid derivatives of nucleosides as antitumoral medicaments
US9512125B2 (en)	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
RU2322450C2 (ru) *	2004-11-25	2008-04-20	Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ"	Модифицированные 5'-фосфонаты азт в качестве активных компонентов для потенциальных противовирусных препаратов
EP1831235B1 (de) *	2004-12-16	2013-02-20	The Regents of The University of California	Arzneimittel für die lungen
EA011039B1 (ru)	2004-12-30	2008-12-30	Медивир Аб	Приемлемые для лечения вич соединения
GB0505781D0 (en)	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
AU2006271164A1 (en) *	2005-07-22	2007-01-25	Giuliani International Limited	Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation
ITRM20050391A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
KR101499783B1 (ko)	2006-04-04	2015-03-09	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	키나제 길항물질
GB0608876D0 (en)	2006-05-05	2006-06-14	Medivir Ab	Combination therapy
US7378401B2 (en)	2006-07-14	2008-05-27	Heidelberg Pharma Gmbh	Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
US9296776B2 (en)	2007-07-09	2016-03-29	Eastern Virginia Medical School	Substituted nucleoside derivatives with antiviral and antimicrobial properties
US20110160232A1 (en)	2007-10-04	2011-06-30	Pingda Ren	Certain chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en)	2008-01-04	2014-03-13	Intellikine, Llc	Certain chemical entities, compositions and methods
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
MX2011000216A (es)	2008-07-08	2011-03-29	Intellikine Inc	Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
WO2010036380A1 (en)	2008-09-26	2010-04-01	Intellikine, Inc.	Heterocyclic kinase inhibitors
WO2010045542A2 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en)	2009-05-07	2010-11-11	Intellikine, Inc.	Heterocyclic compounds and uses thereof
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
JP5951600B2 (ja)	2010-05-21	2016-07-13	インフィニティーファーマシューティカルズ，インコーポレイテッド	キナーゼ調節のための、化合物、組成物および方法
US8901133B2 (en)	2010-11-10	2014-12-02	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20180080358A (ko)	2011-01-10	2018-07-11	인피니티 파마슈티칼스, 인코포레이티드	이소퀴놀린온 및 이의 고체 형태의 제조 방법
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
CN103930422A (zh)	2011-07-19	2014-07-16	无限药品股份有限公司	杂环化合物及其用途
EP2734530A1 (de)	2011-07-19	2014-05-28	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen und ihre verwendung
CN103998442B (zh)	2011-08-29	2016-09-14	无限药品股份有限公司	杂环化合物及其用途
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en)	2012-09-26	2014-04-03	The Regents Of The University Of California	Modulation of ire1
IL291945B2 (en)	2012-11-01	2025-11-01	Infinity Pharmaceuticals Inc	Treatment of cancers using pi3 kinase isoform modulators
CN107056838A (zh)	2013-03-15	2017-08-18	加利福尼亚大学董事会	无环核苷膦酸二酯
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX389256B (es)	2013-10-04	2025-03-20	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP4066834A1 (de)	2014-03-19	2022-10-05	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen zur verwendung in der behandlung von pi3k-gamma-vermittelten erkrankungen
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
DE102014112055A1 (de) *	2014-08-22	2016-02-25	Universität Hamburg	Di- und Triphosphat-Propharmaka
SG11201701957XA (en)	2014-09-15	2017-04-27	Univ California	Nucleotide analogs
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN108349985A (zh)	2015-09-14	2018-07-31	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017048956A1 (en)	2015-09-15	2017-03-23	The Regents Of The University Of California	Nucleotide analogs
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA3028718A1 (en)	2016-06-24	2017-12-28	Infinity Pharmaceuticals, Inc.	Combination therapies
KR20250052378A (ko)	2022-07-21	2025-04-18	안티바 바이오사이언시즈, 인크.	Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
WO2025072232A1 (en) *	2023-09-26	2025-04-03	Board Of Regents Of The University Of Nebraska	Phosphonate prodrugs and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2930904A1 (de) *	1979-07-30	1981-02-19	Kailash Kumar Dr Gauri	Verwendung von 5-alkyl-pyrimidinnucleosiden bei der bekaempfung von krebs
EP0122151B1 (de) *	1983-04-11	1989-02-15	Meito Sangyo Kabushiki Kaisha	Herstellung von primären oder sekundären Phospholipid-Alkohol-Derivaten durch enzymatische Technik
GB2175588B (en) *	1985-04-15	1988-08-10	Toyo Jozo Kk	Nucleoside-phospholipid conjugates
EP0262876B1 (de) *	1986-09-27	1992-04-29	Toyo Jozo Kabushiki Kaisha	Nukleosid-Phospholipid-Konjugat
JP2796089B2 (ja) *	1986-10-06	1998-09-10	旭化成工業株式会社	リン脂質誘導体の製造法
DE3730542A1 (de) *	1987-09-11	1989-04-06	Hoechst Ag	Arzneimittel mit einem gehalt an bestimmten 6-mercaptopurin-derivaten, verwendung dieser 6-mercaptopurin-derivate, verfahren zur herstellung der arzneimittel sowie einige neue 6-mercaptopurin-derivate und verfahren zu deren herstellung
US5463092A (en) *	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5563257A (en) *	1990-08-20	1996-10-08	Boehringer Mannheim Gmbh	Phospholipid derivatives of nucleosides
DE4026265A1 (de) *	1990-08-20	1992-02-27	Boehringer Mannheim Gmbh	Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
DE4111730A1 (de) *	1991-04-10	1992-10-15	Knoll Ag	Neue cytarabin-derivate, ihre herstellung und verwendung
AU668873B2 (en) *	1991-07-12	1996-05-23	Chimerix, Inc.	Antiviral liponucleosides: treatment of hepatitis B
DE4204032A1 (de) *	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
US5512671A (en) *	1993-02-16	1996-04-30	Wake Forest University	Ether lipid-nucleoside covalent conjugates

1994
- 1994-05-28 DE DE4418690A patent/DE4418690A1/de not_active Withdrawn
1995
- 1995-05-23 ES ES95920864T patent/ES2199250T3/es not_active Expired - Lifetime
- 1995-05-23 DK DK95920864T patent/DK0763049T3/da active
- 1995-05-23 UA UA96114469A patent/UA45339C2/uk unknown
- 1995-05-23 EP EP95920864A patent/EP0763049B1/de not_active Expired - Lifetime
- 1995-05-23 WO PCT/EP1995/001951 patent/WO1995032984A1/en not_active Ceased
- 1995-05-23 PT PT95920864T patent/PT763049E/pt unknown
- 1995-05-23 BR BR9507785A patent/BR9507785A/pt not_active Application Discontinuation
- 1995-05-23 JP JP50026296A patent/JP3802057B2/ja not_active Expired - Fee Related
- 1995-05-23 DE DE69531749T patent/DE69531749T2/de not_active Expired - Fee Related
- 1995-05-23 ES ES02008360T patent/ES2206429T3/es not_active Expired - Lifetime
- 1995-05-23 DK DK02008360T patent/DK1229040T3/da active
- 1995-05-23 AU AU26154/95A patent/AU688516B2/en not_active Ceased
- 1995-05-23 SK SK1518-96A patent/SK284207B6/sk not_active IP Right Cessation
- 1995-05-23 CZ CZ19963477A patent/CZ291846B6/cs not_active IP Right Cessation
- 1995-05-23 KR KR1019960706690A patent/KR100279087B1/ko not_active Expired - Fee Related
- 1995-05-23 PT PT02008360T patent/PT1229040E/pt unknown
- 1995-05-23 HU HU9603269A patent/HU220336B/hu not_active IP Right Cessation
- 1995-05-23 MX MX9605809A patent/MX9605809A/es not_active IP Right Cessation
- 1995-05-23 CN CNB951943715A patent/CN1168735C/zh not_active Expired - Fee Related
- 1995-05-23 CA CA002190983A patent/CA2190983C/en not_active Expired - Fee Related
- 1995-05-23 DE DE69530197T patent/DE69530197T2/de not_active Expired - Fee Related
- 1995-05-23 EP EP02008360A patent/EP1229040B8/de not_active Expired - Lifetime
- 1995-05-23 AT AT95920864T patent/ATE236189T1/de not_active IP Right Cessation
- 1995-05-23 AT AT02008360T patent/ATE249472T1/de not_active IP Right Cessation
- 1995-05-23 NZ NZ287434A patent/NZ287434A/en not_active IP Right Cessation
- 1995-05-23 RU RU96124383/04A patent/RU2165429C2/ru active
- 1995-05-24 TW TW084105233A patent/TW420686B/zh active
- 1995-05-25 IL IL113865A patent/IL113865A/en not_active IP Right Cessation
- 1995-05-29 ZA ZA954374A patent/ZA954374B/xx unknown
1996
- 1996-11-21 PL PL95317380A patent/PL185290B1/pl not_active IP Right Cessation
- 1996-11-27 NO NO965054A patent/NO308998B1/no not_active IP Right Cessation
- 1996-11-27 FI FI964727A patent/FI117673B/fi active IP Right Grant
- 1996-11-27 US US08/753,633 patent/US6025343A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR100279087B1 (ko)	2001-01-15
CZ347796A3 (en)	1997-04-16
AU688516B2 (en)	1998-03-12
PT763049E (pt)	2003-08-29
ZA954374B (en)	1996-11-29
CZ291846B6 (cs)	2003-06-18
CA2190983A1 (en)	1995-12-07
EP0763049A1 (de)	1997-03-19
DE69531749T2 (de)	2004-07-29
PT1229040E (pt)	2003-12-31
FI964727L (fi)	1996-11-27
CN1168735C (zh)	2004-09-29
CA2190983C (en)	2006-08-15
DK0763049T3 (da)	2003-07-28
MX9605809A (es)	1997-12-31
NO308998B1 (no)	2000-11-27
NZ287434A (en)	1998-01-26
UA45339C2 (uk)	2002-04-15
HU220336B (hu)	2001-12-28
WO1995032984A8 (en)	2003-01-16
HUT75340A (en)	1997-05-28
SK151896A3 (en)	1997-06-04
PL185290B1 (pl)	2003-04-30
TW420686B (en)	2001-02-01
JPH10500964A (ja)	1998-01-27
DE69530197T2 (de)	2004-01-29
BR9507785A (pt)	1997-09-23
ATE236189T1 (de)	2003-04-15
NO965054D0 (no)	1996-11-27
US6025343A (en)	2000-02-15
EP1229040B8 (de)	2003-11-05
SK284207B6 (en)	2004-11-03
DE69530197D1 (de)	2003-05-08
EP0763049B1 (de)	2003-04-02
CN1154111A (zh)	1997-07-09
EP1229040A2 (de)	2002-08-07
DE4418690A1 (de)	1996-01-11
JP3802057B2 (ja)	2006-07-26
ES2206429T3 (es)	2004-05-16
PL317380A1 (en)	1997-04-01
DK1229040T3 (da)	2003-12-22
HU9603269D0 (en)	1997-01-28
DE69531749D1 (de)	2003-10-16
KR970703354A (ko)	1997-07-03
NO965054L (no)	1997-01-28
ES2199250T3 (es)	2004-02-16
EP1229040B1 (de)	2003-09-10
AU2615495A (en)	1995-12-21
EP1229040A3 (de)	2002-08-21
FI117673B (fi)	2007-01-15
IL113865A (en)	2008-12-29
RU2165429C2 (ru)	2001-04-20
FI964727A0 (fi)	1996-11-27
WO1995032984A1 (en)	1995-12-07
IL113865A0 (en)	1995-08-31

Legal Events

Date

Code

Title

Description

2004-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1229040

Country of ref document: EP

2008-02-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE249472T1 (de)	2003-09-15	Nukleosid-monophosphatderivate, verfahren zu deren herstellung sowie deren verwendung als immunsuppressive arzneimittel
ATE282020T1 (de)	2004-11-15	Verfahren zur herstellung von 2-aminomalonsäure- derivaten
DE69711391D1 (de)	2002-05-02	Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
ATE164582T1 (de)	1998-04-15	1-methylcarbapenemderivate und verfahren zu ihrer herstellung
IT1279045B1 (it)	1997-12-04	Esteri acilici di amminoacidi achirali di gangiclovir e relativi derivati
DE3762860D1 (de)	1990-06-28	2-thiazolylimidazo(1,2-a)pyrimidine und ihre salze, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
NO178025C (no)	1996-01-10	Analogifremgangsmåte for fremstilling av terapeutisk aktive (benzhydryloksyetylpiperidyl)alifatiske syrederivater
DE3574471D1 (de)	1990-01-04	1,6-naphthyridin-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel.
ATE148128T1 (de)	1997-02-15	Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
ATE251144T1 (de)	2003-10-15	Pyrazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
ATE67506T1 (de)	1991-10-15	Pristinamycin-verfahren.
ES8800904A1 (es)	1987-12-01	Procedimiento para preparar derivados de 1,4-dihidropiridina con actividad cardiovascular
ATE229000T1 (de)	2002-12-15	Verfahren zur herstellung von alpha-aminoketonen
DE60011787D1 (de)	2004-07-29	Carbocyclische nukleoside und verfahren zu deren herstellung
ATE154359T1 (de)	1997-06-15	2'-methylidenpyrimidinnukleosidverbindungen, ihre verwendung und verfahren zu ihrer herstellung
DE3781189D1 (de)	1992-09-24	Verfahren zur herstellung von oxazinobenzothiazin-6,6-dioxidderivaten.
DE69015220D1 (de)	1995-02-02	Glycocyamidin-Derivate.
DE58901277D1 (de)	1992-06-04	Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
DK0627419T3 (da)	2000-04-25	Optisk aktive derivater af 1-phenylpyrrolidon og fremgangsmåde til fremstilling deraf
ATE115132T1 (de)	1994-12-15	Derivate des 1,2,5,6-tetrahydropyridin-3- caboxaldehydoxims, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
KR920700196A (ko)	1992-02-19	광학 활성 형태의 스테로이드 측쇄 합성용 중간체 제조 방법